Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.44 |
| ▸ | NPC1 | O15118 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828731 | 0.83 | OPRM1 (0.43) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL10967944 | 0.74 | HTT (0.54) | SMN1; SMN2POLBALDH1A1MEN1KMT2A | |
| Benzene SCHEMBL28160719 | 0.71 | NPC1 (0.49) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL586754 | 0.71 | NPC1 (0.49) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6187585 | 0.69 | MAPT (0.41) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL11729891 | 0.69 | DAO (0.50) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6186179 | 0.69 | MAPT (0.41) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL11198155 | 0.69 | CES2 (0.50) | RAB9ANPC1MAPTSMN1; SMN2POLB | |
| SCHEMBL11198165 | 0.69 | CES2 (0.50) | RAB9ANPC1MAPTSMN1; SMN2POLB | |
| SCHEMBL3210075 | 0.68 | NPC1 (0.50) | RAB9ANPC1MAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143440-A1 | Excellent hypoglycemic agents for treating hyperglycemia, dyslipidemia, hypercholesterolemia, noninsulin-dependent type II diabetes, obesity, glucose intolerance, cardiovascular diabetic complications; reduced side effects due to absence of serotonin reuptake inhibition; imidazoline receptor pathologies | LES LABORATORIES SERVIER (FR) | 2005-06-30 | — | — | US | disclosed |
| US-6875788-B2 | Non-insulin dependent diabetes, antidiabetic agents, dietetics, antilipemic agents, anticholesterol agents, cardiovascular disorders | LES LABORATOIRES SERVIER (FR) | 2005-04-05 | — | — | US | disclosed |
| EP-1413579-B1 | Imidazoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-20040087638-A1 | Imidazoline compounds | LES LABORATOIRES SERVIER (FR) | 2004-05-06 | — | — | US | disclosed |
| EP-1413579-A1 | Imidazoline derivatives, process for the preparation thereof and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087638-A1 | Imidazoline compounds | IRS1, GPR119, INSR | RAB9A 1237/4885NPC1 36/4885MAPT 4618/4885 |
| US-20050143440-A1 | Excellent hypoglycemic agents for treating hyperglycemia, dyslipidemia, hypercholesterolemia, noninsulin-dependent type II diabetes, obesity, glucose intolerance, cardiovascular diabetic complications; reduced side effects due to absence of serotonin reuptake inhibition; imidazoline receptor pathologies | GPR119, INSR, IRS1 | RAB9A 2830/4885NPC1 142/4885MAPT 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.